An Open-label, Multi-center, Long-term Safety Follow-up, Roll-over Study in Patients Who Have Completed a Prior Novartis-sponsored Capmatinib (INC280) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Capmatinib
Phase of Trial: Phase IV
Latest Information Update: 27 Apr 2018
At a glance
- Drugs Capmatinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 23 Apr 2018 Planned End Date changed from 1 Jul 2019 to 20 May 2019.
- 23 Apr 2018 Planned primary completion date changed from 1 Jul 2019 to 15 Jan 2019.
- 22 Aug 2017 Status changed from not yet recruiting to recruiting.